JSPRW
Jasper Therapeutics IncKey Statistics
About Jasper Therapeutics Inc
Jasper Therapeutics Inc. is a pioneering clinical-stage biotechnology company dedicated to revolutionizing the treatment of severe diseases via its innovative hematopoietic cell transplantation platform. The company's lead candidate, JSP191, has demonstrated promising efficacy in early clinical trials targeting blood disorders, supporting its potential to enhance patient outcomes significantly. With a robust pipeline of therapies and an experienced leadership team, Jasper Therapeutics is strategically positioned to advance the frontiers of cell therapy and regenerative medicine, effectively moving its groundbreaking treatments through essential clinical development stages.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-69.94M |
| Operating Margin | 0.00% |
| Return on Equity | -244.20% |
| Return on Assets | -112.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.12 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $23.58M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on JSPRW and any ticker you trade — then tracks every position and per-strategy win rate.